Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
about
Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growthOverexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cellsSLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10Control of CD8 T-Cell Infiltration into Tumors by Vasculature and MicroenvironmentTherapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentUnderstanding high endothelial venules: Lessons for cancer immunologyTargeting and utilizing primary tumors as live vaccines: changing strategiesCCL21 Chemokine Therapy for Lung Cancer.Chemokines as mediators of tumor angiogenesis and neovascularizationCXC chemokines in cancer angiogenesis and metastasesChemokines as mediators of neovascularizationLow CCL-21 expression associates with unfavorable postoperative prognosis of patients with metastatic renal cell carcinoma.CCL21 Cancer Immunotherapy.Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regressionEnhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes.A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.Chemokine regulation of normal and pathologic immune responses.Chemokines: agents for the immunotherapy of cancer?In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2.Dendritic cells: making progress with tumour regression?Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunityGlioma cancer stem cells induce immunosuppressive macrophages/microglia.Chemokines and antitumor immunity: walking the tightrope.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.Local expression of secondary lymphoid tissue chemokine delivered by adeno-associated virus within the tumor bed stimulates strong anti-liver tumor immunity.Intratumoral immunotherapy: using the tumour against itself.Bacterial magnetic particles as a novel and efficient gene vaccine delivery system.The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma.Recent developments in renal cell cancer immunotherapy.Manipulating the chemokine-chemokine receptor network to treat cancer.Oral DNA vaccines target the tumor vasculature and microenvironment and suppress tumor growth and metastasis.Targeting tumors with LIGHT to generate metastasis-clearing immunityInhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis.The anti-tumor effect and increased tregs infiltration mediated by rAAV-SLC vector.Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer.Platelet-derived chemokines: pathophysiology and therapeutic aspects.Chemokine-chemokine receptors in cancer immunotherapy.Chemokines: can effector cells be redirected to the site of the tumor?Regulation of angiostatic chemokines driven by IL-12 and IL-27 in human tumors.
P2860
Q21560837-B0C6EB1A-C99D-41A1-B4E1-48B35E4CB023Q24793668-1AF94C6F-B626-4FEB-ADA5-4965F04AC89BQ24797335-1A5E0F0E-5047-4791-800F-D31F355E59A4Q26799117-60185E48-803E-4E83-9C8A-6BF90327F0AAQ26799123-AA0DF22F-7312-4988-9FCE-1644C5DC3DC3Q27005794-EF5F9759-1A06-4D8B-A7B9-5B6105AACE4BQ27009348-E8BF5C3E-04AE-4EAD-91A6-4B1BE48DB37AQ28248811-3DFE6F1F-82C8-4839-8503-E41DF41C1951Q30427886-BED76C81-5575-4719-9DF9-CC9CD2AF0A7BQ30432791-7F662974-315B-409F-90C2-A71C0B9C4B88Q30438032-FE216570-260E-44B7-9D62-417A595571CDQ33648983-1CB0389B-456A-4EBE-8372-6F0C95F19D6AQ33820300-3A713A40-75BA-46E9-B0B2-3EED518653BAQ33862487-5299A8D7-65CD-45AA-A57A-1AD10A8D7478Q33939602-75E2670C-0341-47D3-8006-F8881B753724Q34205801-7D21C37C-7A31-4F22-8972-A8BD6983D5CFQ34366651-A0748EAB-AC36-4AE4-A441-0317BC9029BBQ34576416-430B304E-0244-4301-8BBF-1CF72A194B9FQ34790338-422B5369-1BDA-4B97-9125-D11119B546A6Q34983449-87E75678-DC55-4FA8-AC55-F12A86CD67BAQ34984596-B9662C3B-B89D-4519-81AB-27CACF66CDC0Q34992518-AFF3EDFC-8FE7-4765-8B54-3A017CC71B17Q35126970-5D623FB3-5B14-4AC6-B417-C785F576CB7AQ35580479-D356F073-0D55-41B3-90A4-E28B5082FCA7Q35713347-7E53135C-D23F-4AC3-8BF4-BCB10C4D5F51Q35947942-06E51B1D-17D1-44A8-B902-62054B75AA66Q35988030-B86C99FB-9B0E-4104-8B89-6313BE89E4FAQ36460540-D71D6153-F2D0-4C62-9D8C-43C1B4DF4ABBQ36684556-712472F5-A37B-438B-9D32-7A6E336A21A2Q36810304-B2FCA79B-A111-495D-AB7F-3A8BB8A1BFFCQ36822184-E2299215-E1BA-44C0-829A-EDE07E3A29AAQ37118147-B59B5A90-E726-49C6-90B0-866556AAE9A7Q37175025-90AEE42C-ADD1-434C-945F-8B7CEA8E3C4CQ37222545-3589F613-2752-46F9-A00B-1834093D596AQ37298417-402B138C-0F84-4501-8685-D7656E7C9B26Q37456503-5469DFDE-7DEA-4E8A-9F73-90204DBF52BBQ37705023-FE461150-5EE8-4BDC-BF82-97EECE023159Q37773282-E822CD09-105E-4167-ADF2-F04B5F36C1B9Q37778693-6FE3ADCA-C689-44C5-AC4B-56B2676FD3AEQ37900430-3710BD50-6864-4F10-8847-5BD82D5E9575
P2860
Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Secondary lymphoid tissue chem ...... t antitumor responses in vivo.
@en
type
label
Secondary lymphoid tissue chem ...... t antitumor responses in vivo.
@en
prefLabel
Secondary lymphoid tissue chem ...... t antitumor responses in vivo.
@en
P2093
P1476
Secondary lymphoid tissue chem ...... t antitumor responses in vivo.
@en
P2093
Dubinett SM
Strieter RM
P304
P356
10.4049/JIMMUNOL.164.9.4558
P407
P50
P577
2000-05-01T00:00:00Z